FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). The grant will allow Complix to accelerate the development of its unique cell penetrating Alphabodies (CPABs), against a range of intracellular disease targets, including cancer. read more
On Wednesday 10 and Thursday 11 October 2012, a delegation of the European Interreg IVC project ETTBio was invited for a site visit in Belgium. Organized by ETTBio’s local partner Vrije Universiteit Brussel (VUB), the visit was intended to give a first impression of good practices occurring in one of the most experienced biotech regions in Europe. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey. read more
Het tweede gedeelte van het ochtendprogramma van het Biobased Delta-congres stond in het teken van een podiumgesprek tussen twee Nederlandse ondernemers en een Vlaamse directrice van een sectorfederatie. Albert Markusse (Suiker Unie), Victor Vreek (Avantium) en Ann de Beuckelaer (FlandersBio) maakten hun opwachting. read more
Galapagos NV (Euronext: GLPG) announced today that it has started its second Phase I clinical study with GLPG0974, a GPR43 inhibitor being developed to treat chronic, neutrophil-driven inflammatory conditions such as inflammatory bowel disease (IBD). In this clinical study, the safety and tolerability of GLPG0974 will be evaluated for 2 weeks in 32 healthy volunteers. Aim of the study is also to confirm the strong biomarker signal and the once-daily (QD) dosing of the compound after 14 days. Results of the study are expected to be reported early next year. read more
Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from KBC Group NV and KBC Private Equity NV. read more